P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) [5][6] that belongs to the G i class of a group of G protein-coupled (GPCR) purinergic receptors. [7] This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides.

To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.

The objectives of this review are to discuss the pharmacological limitations of the P2Y12 inhibitor clopidogrel, and describe the novel alternative P2Y12 inhibitors prasugrel and ticagrelor and the clinical implications of the introduction of these new medicines.

2024年7月14日 · Antiplatelet medicines work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet medicine that may be used. P2Y12 receptor blockers are another group of antiplatelet medicines.

2022年2月3日 · Measures the “On-Treatment Platelet Reactivity” (OTPR) of the ADP P2Y12 receptor. The reference range is 194-418 PRU. Values <194 PRU indicate evidence of P2Y12 inhibitor effect – said another way, low numbers = good thienopyridine antiplatelet activity. Platelet Reactivity Thresholds and Interpretation

The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses.

Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 receptor (platelet receptor for Adenosine 5′ diphosphate) inhibitor for the past two decades.

P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease ...

2025年3月21日 · Objective This systematic review and meta-analysis compared the efficacy and safety of P2Y12 inhibitors versus aspirin monotherapy for secondary prevention in patients with coronary heart disease (CAD), providing evidence for clinical decision-making. Methods Following the PRISMA and AMSTAR2 guidelines, a comprehensive literature search was conducted in …

P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides. The platelet ADP-receptor which has been denominated P2Y 12 receptor is an important target in pharmacotherapy.